Jeffrey B. Cheng

Assistant Professor

University of California
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Supplementary Table S1. Patient cohort: Clinical data and assays Supplementary Table S2. Sample cohort: Clinical data and assays Supplementary Table S3. Pre-ICB bulk RNA-seq cohort, 63 samples Supplementary Table S4. Pre-Post ICB matched bulk RNA-seq, 28 samples, 14 patient pairs Supplementary Table S5. Number of reads for each bulk RNA-seq sample (85 samples) Supplementary Table S6. Tissue single-cell RNA-seq quality control and sample metadata (54 samples) Supplementary Table S7. Blood single-cell RNA-seq quality control and sample metadata (55 samples) Supplementary Table S8. Multiplex immunofluorescence sample cohort (44 samples) Supplementary Table S9. GeoMx sample cohort (15 samples) Supplementary Table S10. CosMx sample cohort (13 samples) Supplementary Table S11: Genes differentially expressed between MCC that respond to anti-PD-1/PD-L1 therapy (n=31) and MCC that do not respond to anti-PD-1/PD-L1 therapy (n=32) in the pre-ICB cohort (n=63). Supplementary Table S12. Enrichr results of differentially expressed genes (FDR

Year:

2024

Supplementary Fig. S1: Patient level heatmaps by assay. Supplementary Fig. S2: Overview of modalities in database. Supplementary Fig. S3: Computational pipeline for single cell RNA-seq data processing. Supplementary Fig. S4: Quality control metrics of tissue single cell data set. Supplementary Fig. S5: Cell type clusters in single-cell PBMC dataset. Supplementary Fig. S6: Myeloid cells in Merkel cell carcinoma. Supplementary Fig. S7: Response to ICB is associated with tumor cell upregulation of an interferon-γ signature. Supplementary Fig. S8: GSEA on tumor cells controlling for proliferation. Supplementary Fig. S9: Dot plot of RNA markers in CD8 clusters (tissue). Supplementary Fig. S10: Clonotype distribution between CD8 T cell lineages. Supplementary Fig. S11: CD8 lineage characterization. Supplementary Fig. S12: Clonality and neoantigen metrics of metrics of CD8 T cells. Supplementary Fig. S13: Comparisons of cell type signatures and cell proportions separated by sample origin. Supplementary Fig. S14: Epitope screening results. Supplementary Fig. S15: Public epitopes. Supplementary Fig. S16: Expression of naïve-like markers on Vδ1 T cells. Supplementary Fig. S17: GeoMx quality control for regions of interest. Supplementary Fig. S18: GeoMx image and differential expression analysis. Supplementary Fig. S19: CosMx quality control for fields of view. Supplementary Fig. S20: CosMx degree of co-localization sensitivity test shows B cell, T cell, pDC, and DC interactions. Supplementary Fig. S21: Pre-post genes. Supplementary Fig. S22: MIXCR analysis of pre-post ICB clonal dynamics. Supplementary Fig. S23: Single cell analysis of pre-post ICB clonal dynamics. Supplementary Fig. S24: Functional convergence of CD8 and γT cells. Supplementary Fig. S25: Graphical model of immune checkpoint response in MCC.

Year:

2024

Supplementary Table S1. Patient cohort: Clinical data and assays Supplementary Table S2. Sample cohort: Clinical data and assays Supplementary Table S3. Pre-ICB bulk RNA-seq cohort, 63 samples Supplementary Table S4. Pre-Post ICB matched bulk RNA-seq, 28 samples, 14 patient pairs Supplementary Table S5. Number of reads for each bulk RNA-seq sample (85 samples) Supplementary Table S6. Tissue single-cell RNA-seq quality control and sample metadata (54 samples) Supplementary Table S7. Blood single-cell RNA-seq quality control and sample metadata (55 samples) Supplementary Table S8. Multiplex immunofluorescence sample cohort (44 samples) Supplementary Table S9. GeoMx sample cohort (15 samples) Supplementary Table S10. CosMx sample cohort (13 samples) Supplementary Table S11: Genes differentially expressed between MCC that respond to anti-PD-1/PD-L1 therapy (n=31) and MCC that do not respond to anti-PD-1/PD-L1 therapy (n=32) in the pre-ICB cohort (n=63). Supplementary Table S12. Enrichr results of differentially expressed genes (FDR

Year:

2024

Supplementary Fig. S1: Patient level heatmaps by assay. Supplementary Fig. S2: Overview of modalities in database. Supplementary Fig. S3: Computational pipeline for single cell RNA-seq data processing. Supplementary Fig. S4: Quality control metrics of tissue single cell data set. Supplementary Fig. S5: Cell type clusters in single-cell PBMC dataset. Supplementary Fig. S6: Myeloid cells in Merkel cell carcinoma. Supplementary Fig. S7: Response to ICB is associated with tumor cell upregulation of an interferon-γ signature. Supplementary Fig. S8: GSEA on tumor cells controlling for proliferation. Supplementary Fig. S9: Dot plot of RNA markers in CD8 clusters (tissue). Supplementary Fig. S10: Clonotype distribution between CD8 T cell lineages. Supplementary Fig. S11: CD8 lineage characterization. Supplementary Fig. S12: Clonality and neoantigen metrics of metrics of CD8 T cells. Supplementary Fig. S13: Comparisons of cell type signatures and cell proportions separated by sample origin. Supplementary Fig. S14: Epitope screening results. Supplementary Fig. S15: Public epitopes. Supplementary Fig. S16: Expression of naïve-like markers on Vδ1 T cells. Supplementary Fig. S17: GeoMx quality control for regions of interest. Supplementary Fig. S18: GeoMx image and differential expression analysis. Supplementary Fig. S19: CosMx quality control for fields of view. Supplementary Fig. S20: CosMx degree of co-localization sensitivity test shows B cell, T cell, pDC, and DC interactions. Supplementary Fig. S21: Pre-post genes. Supplementary Fig. S22: MIXCR analysis of pre-post ICB clonal dynamics. Supplementary Fig. S23: Single cell analysis of pre-post ICB clonal dynamics. Supplementary Fig. S24: Functional convergence of CD8 and γT cells. Supplementary Fig. S25: Graphical model of immune checkpoint response in MCC.

Year:

2024

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a ∼50% response rate to immune checkpoint blockade (ICB) therapy. To identify predictive biomarkers, we integrated bulk and single-cell RNA sequencing (RNA-seq) with spatial transcriptomics from a cohort of 186 samples from 116 patients, including bulk RNA-seq from 14 matched pairs pre- and post-ICB. In nonresponders, tumors show evidence of increased tumor proliferation, neuronal stem cell markers, and IL1. Responders have increased type I/II interferons and preexisting tissue resident (Trm) CD8 or Vδ1 γδ T cells that functionally converge with overlapping antigen-specific transcriptional programs and clonal expansion of public T-cell receptors. Spatial transcriptomics demonstrated colocalization of T cells with B and dendritic cells, which supply chemokines and costimulation. Lastly, ICB significantly increased clonal expansion or recruitment of Trm and Vδ1 cells in tumors specifically in responders, underscoring their therapeutic importance. These data identify potential clinically actionable biomarkers and therapeutic targets for MCC. Significance: MCC serves as a model of ICB response. We utilized the largest-to-date, multimodal MCC dataset ( n = 116 patients) to uncover unique tumor-intrinsic properties and immune circuits that predict response. We identified CD8 Trm and Vδ1 T cells as clinically actionable mediators of ICB response in major histocompatibility complex–high and –low MCCs, respectively.

Year:

2024

Supplementary Table S1. Patient cohort: Clinical data and assays Supplementary Table S2. Sample cohort: Clinical data and assays Supplementary Table S3. Pre-ICB bulk RNA-seq cohort, 63 samples Supplementary Table S4. Pre-Post ICB matched bulk RNA-seq, 28 samples, 14 patient pairs Supplementary Table S5. Number of reads for each bulk RNA-seq sample (85 samples) Supplementary Table S6. Tissue single-cell RNA-seq quality control and sample metadata (54 samples) Supplementary Table S7. Blood single-cell RNA-seq quality control and sample metadata (55 samples) Supplementary Table S8. Multiplex immunofluorescence sample cohort (44 samples) Supplementary Table S9. GeoMx sample cohort (15 samples) Supplementary Table S10. CosMx sample cohort (13 samples) Supplementary Table S11: Genes differentially expressed between MCC that respond to anti-PD-1/PD-L1 therapy (n=31) and MCC that do not respond to anti-PD-1/PD-L1 therapy (n=32) in the pre-ICB cohort (n=63). Supplementary Table S12. Enrichr results of differentially expressed genes (FDR

Year:

2024

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a ∼50% response rate to immune checkpoint blockade (ICB) therapy. To identify predictive biomarkers, we integrated bulk and single-cell RNA sequencing (RNA-seq) with spatial transcriptomics from a cohort of 186 samples from 116 patients, including bulk RNA-seq from 14 matched pairs pre- and post-ICB. In nonresponders, tumors show evidence of increased tumor proliferation, neuronal stem cell markers, and IL1. Responders have increased type I/II interferons and preexisting tissue resident (Trm) CD8 or Vδ1 γδ T cells that functionally converge with overlapping antigen-specific transcriptional programs and clonal expansion of public T-cell receptors. Spatial transcriptomics demonstrated colocalization of T cells with B and dendritic cells, which supply chemokines and costimulation. Lastly, ICB significantly increased clonal expansion or recruitment of Trm and Vδ1 cells in tumors specifically in responders, underscoring their therapeutic importance. These data identify potential clinically actionable biomarkers and therapeutic targets for MCC. Significance: MCC serves as a model of ICB response. We utilized the largest-to-date, multimodal MCC dataset ( n = 116 patients) to uncover unique tumor-intrinsic properties and immune circuits that predict response. We identified CD8 Trm and Vδ1 T cells as clinically actionable mediators of ICB response in major histocompatibility complex–high and –low MCCs, respectively.

Year:

2024

Supplementary Fig. S1: Patient level heatmaps by assay. Supplementary Fig. S2: Overview of modalities in database. Supplementary Fig. S3: Computational pipeline for single cell RNA-seq data processing. Supplementary Fig. S4: Quality control metrics of tissue single cell data set. Supplementary Fig. S5: Cell type clusters in single-cell PBMC dataset. Supplementary Fig. S6: Myeloid cells in Merkel cell carcinoma. Supplementary Fig. S7: Response to ICB is associated with tumor cell upregulation of an interferon-γ signature. Supplementary Fig. S8: GSEA on tumor cells controlling for proliferation. Supplementary Fig. S9: Dot plot of RNA markers in CD8 clusters (tissue). Supplementary Fig. S10: Clonotype distribution between CD8 T cell lineages. Supplementary Fig. S11: CD8 lineage characterization. Supplementary Fig. S12: Clonality and neoantigen metrics of metrics of CD8 T cells. Supplementary Fig. S13: Comparisons of cell type signatures and cell proportions separated by sample origin. Supplementary Fig. S14: Epitope screening results. Supplementary Fig. S15: Public epitopes. Supplementary Fig. S16: Expression of naïve-like markers on Vδ1 T cells. Supplementary Fig. S17: GeoMx quality control for regions of interest. Supplementary Fig. S18: GeoMx image and differential expression analysis. Supplementary Fig. S19: CosMx quality control for fields of view. Supplementary Fig. S20: CosMx degree of co-localization sensitivity test shows B cell, T cell, pDC, and DC interactions. Supplementary Fig. S21: Pre-post genes. Supplementary Fig. S22: MIXCR analysis of pre-post ICB clonal dynamics. Supplementary Fig. S23: Single cell analysis of pre-post ICB clonal dynamics. Supplementary Fig. S24: Functional convergence of CD8 and γT cells. Supplementary Fig. S25: Graphical model of immune checkpoint response in MCC.

Year:

2024

Supplementary Fig. S1: Patient level heatmaps by assay. Supplementary Fig. S2: Overview of modalities in database. Supplementary Fig. S3: Computational pipeline for single cell RNA-seq data processing. Supplementary Fig. S4: Quality control metrics of tissue single cell data set. Supplementary Fig. S5: Cell type clusters in single-cell PBMC dataset. Supplementary Fig. S6: Myeloid cells in Merkel cell carcinoma. Supplementary Fig. S7: Response to ICB is associated with tumor cell upregulation of an interferon-γ signature. Supplementary Fig. S8: GSEA on tumor cells controlling for proliferation. Supplementary Fig. S9: Dot plot of RNA markers in CD8 clusters (tissue). Supplementary Fig. S10: Clonotype distribution between CD8 T cell lineages. Supplementary Fig. S11: CD8 lineage characterization. Supplementary Fig. S12: Clonality and neoantigen metrics of metrics of CD8 T cells. Supplementary Fig. S13: Comparisons of cell type signatures and cell proportions separated by sample origin. Supplementary Fig. S14: Epitope screening results. Supplementary Fig. S15: Public epitopes. Supplementary Fig. S16: Expression of naïve-like markers on Vδ1 T cells. Supplementary Fig. S17: GeoMx quality control for regions of interest. Supplementary Fig. S18: GeoMx image and differential expression analysis. Supplementary Fig. S19: CosMx quality control for fields of view. Supplementary Fig. S20: CosMx degree of co-localization sensitivity test shows B cell, T cell, pDC, and DC interactions. Supplementary Fig. S21: Pre-post genes. Supplementary Fig. S22: MIXCR analysis of pre-post ICB clonal dynamics. Supplementary Fig. S23: Single cell analysis of pre-post ICB clonal dynamics. Supplementary Fig. S24: Functional convergence of CD8 and γT cells. Supplementary Fig. S25: Graphical model of immune checkpoint response in MCC.

Year:

2024

Year:

2024

Year:

2022

Collaborators (19)

Xuefeng Wang

Associate Member/Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Brian Pierce

University of Maryland

UNITED STATES
View details

Vernon Sondak

Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Nikhil Khushalani

Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Ari Molofsky

Professor

University of California, San Francisco

UNITED STATES
View details

Xinlei Mi

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Alessandra Veinbachs

Life Sciences Research Professional

Stanford University

UNITED STATES
View details

Raymond Jaihyun Cho

Professor

UCSF Medical Center

UNITED STATES
View details

Jeffrey North

-

UNITED STATES
View details

Tiffany Scharschmidt

Professor and Vice Chair of Research

University of California, San Francisco

UNITED STATES
View details

Amod Sarnaik

Senior Member / Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Jaehyuk Choi

Associate Professor

Yale University School of Medicine

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Jonathan S. Zager

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Andrew Brohl

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Spencer Ng

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Kenneth Tsai

Vice Chair of Research, Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Sergei Koralov

Associate Prof

NYU School of Medicine

UNITED STATES
View details

Suzanne Noble

Associate Professor

University of California, San Francisco

UNITED STATES
View details